|
|
Vaccine Detail
|
Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007161
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: KLK, Cd80, ICAM1, CD58
- KLK3
gene engineering:
- Cd80
gene engineering:
- ICAM1
gene engineering:
- CD58
gene engineering:
- Preparation: Recombinant fowlpox virus is used to encode an alteration in the HLA-A2 specific epitope and three co-stimulatory molecules, B7.1, ICAM-1 and LFA-3 (DiPaola et al., 2006).
- Description: This is for Prostate Cancer (NCT00108732). A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells (NCIT_C29560).
|
| Host Response |
|
|
| References |
DiPaola et al., 2006: DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. Journal of translational medicine. 2006; 4; 1. [PubMed: 16390546].
NCIT_C29560: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29560]
NCT00108732: [https://clinicaltrials.gov/ct2/show/NCT00108732?term=Fowlpox-PSA-TRICOM+Vaccine&rank=1]
|
|
